Aphaia Pharma to Participate in the LSX Leaders Inv€$tival Showcase
07 Nov 2022
Collaborate
Aphaia Pharma to Participate in the LSX Leaders Inv€$tival Showcase
ZUG, Switzerland, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of metabolic diseases, today announced that it will participate in the LSX Leaders Inv€$tival Showcase, to be held November 14, 2022, in London as the pre-day to the Jefferies London Healthcare Conference, November 15-17, 2022.
Members of the management team will present a corporate overview at the LSX Inv€$tival Showcase and will be available for one-on-one meetings during the LSX Inv€$tival Showcase and the Jefferies conference.
Presentation Details
LSX Inv€$tival Showcase
Stage: Biotech Growth Stage (pre-series B), Company showcase presentations
Date and Time: Monday, November 14, 3:45 p.m. GMT
About LSX Inv€$tival Showcase
The Inv€$tival Showcase is an LSX Leaders event in partnership with the global investment bank Jefferies and the annual European Lifestars Awards, with the showcase serving as the pre-day to Jefferies London Healthcare Conference. The event returns for its seventh year to connect early, growth stage, public life science, and health technology companies to global capital and deal-makers during the largest week in European life sciences investment.
Aphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug formulations to restore endogenous hormone release from nutrient-sensing cells in the GI tract to treat and prevent metabolic disorders such as obesity and associated diseases. Aphaia’s lead candidate, APH-012, a glucose formulation, has been shown to safely restore endogenous hormone release in individuals with obesity. APH-012 is now being evaluated in a Phase 2 trial in the U.S. and Germany for chronic weight management and is preparing to be evaluated in a second Phase 2 trial for the improvement of pre-diabetes in individuals with a pathological oral glucose tolerance test (OGTT). The versatile design of Aphaia’s technology platform provides an opportunity for the development of treatments for multiple disease patterns.
Aphaia Investor Contact
Günter Jucho
Chief Financial Officer
jucho@aphaiapharma.com
Media Contact
Jordyn Temperato
LifeSci Communications
AphaiaPharma@lifescicomms.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.